Triple

T32226678
Position Surface form Disambiguated ID Type / Status
Subject FOLFIRI regimen E823219 entity
Predicate doseAdjustment P61679 FINISHED
Object dose reduction may be required in patients with UGT1A1*28 polymorphism for irinotecan LITERAL FINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: dose reduction may be required in patients with UGT1A1*28 polymorphism for irinotecan | Statement: [FOLFIRI regimen, doseAdjustment, dose reduction may be required in patients with UGT1A1*28 polymorphism for irinotecan]
PD Predicate disambiguation gpt-5-mini-2025-08-07
Target predicate: doseAdjustment
Context triple: [FOLFIRI regimen, doseAdjustment, dose reduction may be required in patients with UGT1A1*28 polymorphism for irinotecan]
  • A. doseAdjustmentRequiredIn chosen
    Indicates that a change in the amount or frequency of a treatment or medication is necessary within a specified context, such as a condition, setting, or patient group.
  • B. dosageAdded
    Indicates that an additional amount of a substance or medication has been administered or incorporated into an existing dosage.
  • C. doseRegimen
    Indicates the specific schedule, frequency, and amount with which a dose of a substance or medication is to be administered.
  • D. hasDosingRegimen
    Indicates that an entity is associated with a specific dosing regimen, defining how and when a dose is to be administered.
  • E. hasMaintenanceDose
    Indicates that an entity is associated with a specific ongoing dose used to maintain a desired therapeutic effect after initial treatment.
  • F. None of above.

Provenance (3 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69f3490b4f948190b99e4f999f5be25f completed April 30, 2026, 12:20 p.m.
NER Named-entity recognition batch_69f6bbcbd31c8190a482a5fd5040410d completed May 3, 2026, 3:06 a.m.
PD Predicate disambiguation batch_69f6b632cf788190a3d0c08cd026b84b completed May 3, 2026, 2:42 a.m.
Created at: May 1, 2026, 12:38 a.m.